Lancet publishes PhIII data on Kyowa Hakko’s Poteligeo
The Lancet has published data from Kyowa Hakko Kirin Co’s successful Phase III trial of immunotherapy Poteligeo underpinning its recent approval in the US to treat in patients with cutaneous T-cell lymphoma (CTCL).
Read More
